亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and Safety of Antidepressants in Patients With Comorbid Depression and Medical Diseases

医学 共病 萧条(经济学) 精神科 梅德林 心理学 政治学 法学 经济 宏观经济学
作者
Ole Köhler‐Forsberg,Victoria Stiglbauer,Jelena Brasanac,Woo Ri Chae,Frederike Wagener,Kim Zimbalski,Oskar Hougaard Jefsen,Shuyan Liu,Malik R. Seals,Stefanie Gamradt,Christoph U. Correll,Stefan M. Gold,Christian Otte
出处
期刊:JAMA Psychiatry [American Medical Association]
卷期号:80 (12): 1196-1196 被引量:31
标识
DOI:10.1001/jamapsychiatry.2023.2983
摘要

Importance: Every third to sixth patient with medical diseases receives antidepressants, but regulatory trials typically exclude comorbid medical diseases. Meta-analyses of antidepressants have shown small to medium effect sizes, but generalizability to clinical settings is unclear, where medical comorbidity is highly prevalent. Objective: To perform an umbrella systematic review of the meta-analytic evidence and meta-analysis of the efficacy and safety of antidepressant use in populations with medical diseases and comorbid depression. Data Sources: PubMed and EMBASE were searched from inception until March 31, 2023, for systematic reviews with or without meta-analyses of randomized clinical trials (RCTs) examining the efficacy and safety of antidepressants for treatment or prevention of comorbid depression in any medical disease. Study Selection: Meta-analyses of placebo- or active-controlled RCTs studying antidepressants for depression in individuals with medical diseases. Data Extraction and Synthesis: Data extraction and quality assessment using A Measurement Tool for the Assessment of Multiple Systematic Reviews (AMSTAR-2 and AMSTAR-Content) were performed by pairs of independent reviewers following PRISMA guidelines. When several meta-analyses studied the same medical disease, the largest meta-analysis was included. Random-effects meta-analyses pooled data on the primary outcome (efficacy), key secondary outcomes (acceptability and tolerability), and additional secondary outcomes (response and remission). Main Outcomes and Measures: Antidepressant efficacy presented as standardized mean differences (SMDs) and tolerability (discontinuation for adverse effects) and acceptability (all-cause discontinuation) presented as risk ratios (RRs). Results: Of 6587 references, 176 systematic reviews were identified in 43 medical diseases. Altogether, 52 meta-analyses in 27 medical diseases were included in the evidence synthesis (mean [SD] AMSTAR-2 quality score, 9.3 [3.1], with a maximum possible of 16; mean [SD] AMSTAR-Content score, 2.4 [1.9], with a maximum possible of 9). Across medical diseases (23 meta-analyses), antidepressants improved depression vs placebo (SMD, 0.42 [95% CI, 0.30-0.54]; I2 = 76.5%), with the largest SMDs for myocardial infarction (SMD, 1.38 [95% CI, 0.82-1.93]), functional chest pain (SMD, 0.87 [95% CI, 0.08-1.67]), and coronary artery disease (SMD, 0.83 [95% CI, 0.32-1.33]) and the smallest for low back pain (SMD, 0.06 [95% CI, 0.17-0.39]) and traumatic brain injury (SMD, 0.08 [95% CI, -0.28 to 0.45]). Antidepressants showed worse acceptability (24 meta-analyses; RR, 1.17 [95% CI, 1.02-1.32]) and tolerability (18 meta-analyses; RR, 1.39 [95% CI, 1.13-1.64]) compared with placebo. Antidepressants led to higher rates of response (8 meta-analyses; RR, 1.54 [95% CI, 1.14-1.94]) and remission (6 meta-analyses; RR, 1.43 [95% CI, 1.25-1.61]) than placebo. Antidepressants more likely prevented depression than placebo (7 meta-analyses; RR, 0.43 [95% CI, 0.33-0.53]). Conclusions and Relevance: The results of this umbrella systematic review of meta-analyses found that antidepressants are effective and safe in treating and preventing depression in patients with comorbid medical disease. However, few large, high-quality RCTs exist in most medical diseases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大意的山水完成签到,获得积分10
1秒前
迷路万天完成签到,获得积分10
2秒前
3秒前
绿鬼蓝完成签到 ,获得积分10
3秒前
域尔完成签到,获得积分10
3秒前
4秒前
6秒前
7秒前
清平道人完成签到,获得积分0
9秒前
maoxiaodi发布了新的文献求助10
11秒前
白华苍松发布了新的文献求助10
13秒前
喵喵张完成签到 ,获得积分10
13秒前
111完成签到 ,获得积分10
15秒前
田様的应助被听话的含羞草采纳,获得10
16秒前
轨迹。完成签到 ,获得积分10
17秒前
在水一方的应助被美满惜雪采纳,获得10
22秒前
顾矜的应助被谌坚采纳,获得10
24秒前
24秒前
橱窗完成签到,获得积分10
25秒前
25秒前
LL完成签到 ,获得积分10
26秒前
fan完成签到 ,获得积分10
27秒前
27秒前
hfhkjh完成签到,获得积分10
28秒前
俏皮的绮波完成签到,获得积分10
28秒前
28秒前
cfyoung发布了新的文献求助10
29秒前
cfyoung发布了新的文献求助10
29秒前
30秒前
30秒前
友好胜完成签到 ,获得积分0
30秒前
帅气忻完成签到 ,获得积分10
30秒前
31秒前
31秒前
cfyoung发布了新的文献求助10
32秒前
cfyoung发布了新的文献求助10
32秒前
cfyoung发布了新的文献求助10
32秒前
cfyoung发布了新的文献求助10
32秒前
cfyoung发布了新的文献求助10
33秒前
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184964
求助须知:如何正确求助?哪些是违规求助? 9573917
关于积分的说明 21833687
捐赠科研通 7782425
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558672
邀请新用户注册赠送积分活动 2481161